Developing disease-modifying therapies in Parkinson’s Disease: The buzz about LRRK2 kinase inhibitors by Andrew B. West, PhDPhoto Credit: Grove Ayers Read More Basic ScienceAndrew B. West, PhDJuly 10, 2017LRRK2, Michael J Fox, PPMI, Genetics, July 2017, one, FirstComment
